IDEXX Laboratories Inc. (IDXX) earns a Roarable Rating of B- (Buy) with 70/100 RQD Confidence. High-quality cash engine (61.8% gross margin, 30% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
As of 2026-11-03, IDEXX Laboratories Inc. (NASDAQ: IDXX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $551.21 (-4.30% 1D, market cap $43.42B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, IDXX ranks #72 in composite RQD confidence.
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), IDXX carries a Roarable B- (70/100 RQD), trailing P/E of 42.8x, gross margin of 61.8%, and ROIC of 29.6%. By comparison, LNTH (Lantheus Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 28.0x, ROIC 20.3%, cap $6.56B) and ORKA (Oruka Therapeutics Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -18.8%, cap $6.41B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while IDXX leads on capital efficiency (29.6% ROIC).
Per IDXX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000874716), IDEXX Laboratories Inc. generated $4.30B in revenue (+10.4% YoY), $1.06B in net income, and $1.06B in free cash flow against $3.35B in total assets and $374.8M in total debt. Key quantitative strengths: Strong cash generator (61.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
SEC XBRL FY 2025 (10-K): 24.6% FCF Margin ($1.06B FCF) & 61.8% Gross Margin
Altman Z-Score 20.99 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 9/9
Macro rate sensitivity & RSI-14 (50.5) create a -10 pt regime headwind
Even with a 70/100 (B-) score, IDXX faces multiple-compression risk if 42.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Sensitive to high interest rates and tighter Federal Reserve market liquidity.
Priced at 43x earnings—high expectations leave less room for a lukewarm quarter.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($535.00) or 200D SMA ($570.57) invalidates the momentum regime and cuts Target Base ($580.98) toward Bear Floor ($451.99).
IDEXX Laboratories Inc. (IDXX) dropped -4.30% to $551.21, trading at 19% of its 52-week range ($500.61 – $769.98). High-quality cash engine (61.8% gross margin, 30% return on capital) with steady institutional support.
Yahoo Finance report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
High hopes of an AI rally were dashed on Monday.
The veterinary diagnostics company saw sales and profit grow more than Wall Street expected.
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on IDXX today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for IDXX. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, IDEXX Laboratories Inc. (IDXX) ranks #72 by composite RQD confidence (70/100, grade B-) and #42 by equity capitalization ($43.42B). Within this direct 5-issuer industry benchmark cohort, LNTH leads on earnings valuation at 28.0x trailing P/E, while IDXX leads on capital efficiency and profitability with 29.6% ROIC and 61.8% gross margin. LNTH currently holds the highest overall quantitative score in the immediate peer group at 76/100 (B+) compared with IDXX at 70/100 (B-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| IDXX
ACTIVE
IDEXX Laboratories Inc. | B- | 70/100 | 42.8x | 61.8% | 29.6% | -4.30% | $43.42B | Benchmark Subject |
| LNTH Lantheus Holdings Inc. | B+ | 76/100 | 28.0x | 61.1% | 20.3% | +0.14% | $6.56B | /lnth-vs-idxx → |
| ORKA Oruka Therapeutics Inc. | D+ | 53/100 | — | — | -18.8% | +0.23% | $6.41B | /orka-vs-idxx → |
| NEOG Neogen Corporation | D | 47/100 | — | 46.9% | -0.6% | -3.59% | $2.58B | /neog-vs-idxx → |
| CLDX Celldex Therapeutics Inc. | E | 29/100 | — | 87.1% | -35.0% | +0.70% | $2.36B | /cldx-vs-idxx → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), IDEXX Laboratories Inc. (IDXX) reported GAAP revenue of $4.30B (+10.4% vs. FY2024 revenue of $3.90B , and +17.6% cumulative change since FY2023) , GAAP net income of $1.06B, operating cash flow of $1.18B, and free cash flow of $1.06B (+30.8% YoY). On the balance sheet, IDXX closed FY2025 with $3.35B in total assets against $374.8M in total debt (Altman Z-Score: 20.99, Piotroski F-Score: 9/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $4.30B | $1.06B | $1.18B | $1.06B | $3.35B | $374.8M |
| FY2024 (FY) | 2024-12-31 | $3.90B | $887.9M | $929.0M | $808.1M | $3.29B | $449.8M |
| FY2023 (FY) | 2023-12-31 | $3.66B | $845.0M | $906.5M | $741.8M | $24.96B | $5.84B |
As of 2026-11-03, IDEXX Laboratories Inc. (NASDAQ: IDXX) is rated B- (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 70/100 at a spot price of $551.21 (-4.30% 1D, market cap $43.42B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 10/20, SEC Balance-Sheet Forensics 18/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 13/20. Across 1015 tracked Health Care issuers, IDXX ranks #72 in composite RQD confidence.
Within the Health Care sector (Biotechnology: In Vitro & In Vivo Diagnostic Substances), IDXX carries a Roarable B- (70/100 RQD), trailing P/E of 42.8x, gross margin of 61.8%, and ROIC of 29.6%. By comparison, LNTH (Lantheus Holdings Inc.) holds a B+ grade (76/100 RQD, P/E 28.0x, ROIC 20.3%, cap $6.56B) and ORKA (Oruka Therapeutics Inc.) posts a D+ grade (53/100 RQD, P/E N/A, ROIC -18.8%, cap $6.41B). Among the 5-stock peer group, LNTH leads on earnings multiple (28.0x) while IDXX leads on capital efficiency (29.6% ROIC).
Per IDXX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000874716), IDEXX Laboratories Inc. generated $4.30B in revenue (+10.4% YoY), $1.06B in net income, and $1.06B in free cash flow against $3.35B in total assets and $374.8M in total debt. Key quantitative strengths: Strong cash generator (61.8% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Sensitive to high interest rates and tighter Federal Reserve market liquidity. Institutional options positioning shows a 50% call / 50% put premium split.
IDXX last traded at $551.21 (-4.30% on volume of 1,174,197 shares), positioning the stock +3.03% above its 50-day simple moving average ($535.00) and -3.39% below its 200-day simple moving average ($570.57). Across its 52-week range of $500.61 to $769.98, IDXX sits at the 18.8% percentile with a 14-day RSI of 50.5 (NEUTRAL RANGE) and an implied next-earnings move of ±5.4% ($521.44 to $580.98).
IDEXX Laboratories Inc. (IDXX) earns a live Roarable RQD composite score of 70/100, corresponding to a B- letter grade (Roarable Buy) at a spot price of $551.21 (-4.30% 1D, market capitalization $43.42B).
IDEXX Laboratories Inc. Is a NASDAQ-listed issuer in the Health Care sector, within the Biotechnology: In Vitro & In Vivo Diagnostic Substances industry (per the company profile). Specific product lines, customer segments, and revenue mix are — The profile does not describe how the company makes money beyond its sector classification.
In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), IDEXX Laboratories Inc. (IDXX) reported $4.30B in annual revenue (up from $3.90B in FY2024, +10.4% YoY) and $1.06B in GAAP net income. Over the multi-year SEC filing window from FY2023 ($3.66B revenue, $845.0M net income) through FY2025, IDXX scaled operating cash flow to $1.18B and free cash flow to $1.06B, backed by $3.35B in total assets against $374.8M in total debt.
Operating in Biotechnology: In Vitro & In Vivo Diagnostic Substances (Health Care), IDXX carries a macro regime beta of 0.89 and gross margin of 61.8%.
Real-time company headlines, analyst actions, and sector developments for IDEXX Laboratories Inc. (IDXX) • Click "Debate This Headline" to argue it in the Roar Pit below
Yahoo Finance report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
StockInvest.us report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
Investing.com report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
GuruFocus report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
Yahoo Finance report covering IDEXX Laboratories Inc. (IDXX) market action, institutional positioning, and fundamental catalysts.
Here is why I am bullish on IDXX here at $551.21: The stock carries a 29.6% ROIC, an Altman Z of 20.99, and a Piotroski F of 9/9, supported by revenue growth from $3.66B to $4.30B across three fiscal years.. Compare IDXX's 31.6% operating margin and 29.6% ROIC against the rest of Biotechnology: In Vitro & In Vivo Diagnostic Substances. As long as cash conversion holds up, dips toward $523.65 are getting bought.
Both sides have a point here — IDXX's 18/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
At a P/E (TTM) of 42.8 and EV/EBITDA of 31.1, with a 2.33% FCF yield, the valuation leaves little room for growth to disappoint.. Look at the math on IDXX: paying 42.8x trailing P/E for 29.6% ROIC and 31.6% operating margins leaves zero margin of safety if Biotechnology: In Vitro & In Vivo Diagnostic Substances demand softens. I'd wait for a retest of $485.06 before getting long.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).